← Leaderboards

Amanda G Paulovich

Fred Hutchinson Cancer Research Center

Google Scholar ↗PubMed ↗ORCID ↗

$38,180,578

Attributed

$56,669,169

Total exposure

17

Grants

16

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.1M · FY2005–25

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$62,818,577 · 19

By mechanism

U01$16,905,879 · 5

U24$16,181,409 · 1

R01$13,800,377 · 5

U2C$5,203,778 · 3

RC2$4,800,000 · 1

U19$2,831,107 · 1

Top collaborators

Most similar at Fred Hutchinson Cancer Research Center

Same institution · by research overlap

Jennifer A. Doherty$9,064,784
Pei Wang$7,634,998

Others in their field

Top investigators on “Proteins”

David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
Randall J Bateman · Washington University$187,292,085
Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
Reisa A. Sperling · Banner Health$145,046,481
Barton F Haynes · Duke University$136,029,850
Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280

Research focus

ProteinsBaseMalignant NeoplasmsMultiple Reaction MonitoringMass Spectrum AnalysisProteomicsResponseTissuesGenomicsValidationMalignant Breast NeoplasmWomanSamplingBiological MarkersLaboratoriesTechnologyPerformancePlasmaComplementPathway InteractionsTumorFollow-UpBreastDna Damage

Grant awards (82)

Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies$1,190,547

U01 · FY2025 · CA · contact PI

Breast-cancer focused biomarker characterization center employing targeted mass spec assays in a CLIA environment$1,056,723

U2C · FY2025 · CA · contact PI

Clinical translation of a NexGen platform for quantifying protein networks in human biospecimens$809,002

R01 · FY2025 · CA · contact PI

Optimizing pre-analytical variables for reliable mass spectrometry-based quantification of immunomodulatory proteins in cerebrospinal fluid in pediatric neuro-oncology trials$440,171

U01 · FY2025 · CA · contact PI

Admin Core$432,004

U2C · FY2025 · CA · contact PI

Core - Biomarker Developmental Laboratory (BDL)$178,577

U2C · FY2025 · CA · contact PI

Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies$1,122,409

U01 · FY2024 · CA · contact PI

Breast-cancer focused biomarker characterization center employing targeted mass spec assays in a CLIA environment$1,011,318

U2C · FY2024 · CA · contact PI

Clinical translation of a NexGen platform for quantifying protein networks in human biospecimens$837,288

R01 · FY2024 · CA · contact PI

Core - Biomarker Developmental Laboratory (BDL)$551,928

U2C · FY2024 · CA · contact PI

Admin Core$428,269

U2C · FY2024 · CA · contact PI

Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies$1,156,887

U01 · FY2023 · CA · contact PI

Breast-cancer focused biomarker characterization center employing targeted mass spec assays in a CLIA environment$792,490

U2C · FY2023 · CA · contact PI

Clinical translation of a NexGen platform for quantifying protein networks in human biospecimens$692,845

R01 · FY2023 · CA · contact PI

Core - Biomarker Developmental Laboratory (BDL)$577,873

U2C · FY2023 · CA · contact PI

Admin Core$174,596

U2C · FY2023 · CA · contact PI

Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies$1,253,006

U01 · FY2022 · CA · contact PI

Clinical translation of a NexGen platform for quantifying protein networks in human biospecimens$685,897

R01 · FY2022 · CA · contact PI

Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$951,279

U01 · FY2021 · CA · contact PI

Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$811,228

U01 · FY2021 · CA · contact PI

Clinical translation of a NexGen platform for quantifying protein networks in human biospecimens$702,365

R01 · FY2021 · CA · contact PI

A unique approach combining avatar mice and targeted mass spectrometry to identify blood biomarkers for early detection of breast cancer$187,791

U01 · FY2021 · CA · contact PI

Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$1

U01 · FY2021 · CA · contact PI

Clinical translation of a NexGen platform for quantifying protein networks in human biospecimens$1

R01 · FY2021 · CA · contact PI

Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$1,423,336

U01 · FY2020 · CA · contact PI

Clinical translation of a NexGen platform for quantifying protein networks in human biospecimens$707,046

R01 · FY2020 · CA · contact PI

Proteogenomic Studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$440,000

U01 · FY2020 · CA · contact PI

A unique approach combining avatar mice and targeted mass spectrometry to identify blood biomarkers for early detection of breast cancer$436,457

U01 · FY2020 · CA · contact PI

A unique approach combining avatar mice and targeted mass spectrometry to identify blood biomarkers for early detection of breast cancer$147,634

U01 · FY2020 · CA · contact PI

Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$1,394,182

U01 · FY2019 · CA · contact PI

Clinical translation of a NexGen platform for quantifying protein networks in human biospecimens$737,466

R01 · FY2019 · CA · contact PI

A unique approach combining avatar mice and targeted mass spectrometry to identify blood biomarkers for early detection of breast cancer$541,311

U01 · FY2019 · CA · contact PI

Validation of a disposable biospecimen collection system with integral refrigeration for preserving the phosphoproteome$341,440

R21 · FY2019 · CA · contact PI

Project-002$44,780

U01 · FY2019 · CA · contact PI

Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$1,441,604

U01 · FY2018 · CA · contact PI

A unique approach combining avatar mice and targeted mass spectrometry to identify blood biomarkers for early detection of breast cancer$822,049

U01 · FY2018 · CA · contact PI

Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$440,000

U01 · FY2018 · CA · contact PI

Validation of a disposable biospecimen collection system with integral refrigeration for preserving the phosphoproteome$280,976

R21 · FY2018 · CA · contact PI

Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$1,507,572

U01 · FY2017 · CA · contact PI

A unique approach combining avatar mice and targeted mass spectrometry to identify blood biomarkers for early detection of breast cancer$565,399

U01 · FY2017 · CA · contact PI

Proteo-genomic Discovery, Prioritization and Verification of Cancer Biomarkers$825,543

U24 · FY2016 · CA

A unique approach combining avatar mice and targeted mass spectrometry to identify blood biomarkers for early detection of breast cancer$588,236

U01 · FY2016 · CA · contact PI

Discovering tissue-specific biomarkers of radiation injury in SILAC-labeled mice$440,000

R01 · FY2016 · AI · contact PI

Proteo-genomic Discovery, Prioritization and Verification of Cancer Biomarkers$3,155,021

U24 · FY2015 · CA

Discovering tissue-specific biomarkers of radiation injury in SILAC-labeled mice$544,523

R01 · FY2015 · AI · contact PI

Advanced development of immuno-MRM technology to analyze archived cancer tissues$411,968

R33 · FY2015 · CA · contact PI

Proteo-genomic Discovery, Prioritization and Verification of Cancer Biomarkers$3,023,578

U24 · FY2014 · CA

Discovering tissue-specific biomarkers of radiation injury in SILAC-labeled mice$440,000

R01 · FY2014 · AI · contact PI

Advanced development of immuno-MRM technology to analyze archived cancer tissues$399,609

R33 · FY2014 · CA · contact PI

Population-based study of DNA damage response markers of prognosis in breast canc$141,126

P50 · FY2014 · CA · contact PI

Proteo-genomic Discovery, Prioritization and Verification of Cancer Biomarkers$3,019,843

U24 · FY2013 · CA

Discovering tissue-specific biomarkers of radiation injury in SILAC-labeled mice$440,000

R01 · FY2013 · AI · contact PI

Advanced development of immuno-MRM technology to analyze archived cancer tissues$430,968

R33 · FY2013 · CA · contact PI

Population-based study of DNA damage response markers of prognosis in breast canc$195,360

P50 · FY2013 · CA · contact PI

Proteo-genomic Discovery, Prioritization and Verification of Cancer Biomarkers$3,122,514

U24 · FY2012 · CA

Cross-species network approach to predict epistatic cancer susceptibility genes$535,355

R01 · FY2012 · CA · contact PI

Discovering tissue-specific biomarkers of radiation injury in SILAC-labeled mice$440,000

R01 · FY2012 · AI · contact PI

Minimizing mass panic with saliva tests for radiation exposure$431,244

R01 · FY2012 · AI · contact PI

Population-based study of DNA damage response markers of prognosis in breast canc$382,865

P50 · FY2012 · CA · contact PI

Proteo-genomic Discovery, Prioritization and Verification of Cancer Biomarkers$3,034,910

U24 · FY2011 · CA

Cross-species network approach to predict epistatic cancer susceptibility genes$551,809

R01 · FY2011 · CA · contact PI

Minimizing mass panic with saliva tests for radiation exposure$431,244

R01 · FY2011 · AI · contact PI

Population-based study of DNA damage response markers of prognosis in breast canc$311,890

P50 · FY2011 · CA · contact PI

Phenotype-based approach to find gene interactions underlying breast cancer risk$259,494

R01 · FY2011 · CA · contact PI

Measurement of Cancer-Associated Biomarker Proteins in Complex Biological Samples$1,594,648

RC2 · FY2010 · CA · contact PI

Cross-species network approach to predict epistatic cancer susceptibility genes$586,147

R01 · FY2010 · CA · contact PI

Minimizing mass panic with saliva tests for radiation exposure$435,600

R01 · FY2010 · AI · contact PI

Phenotype-based approach to find gene interactions underlying breast cancer risk$267,520

R01 · FY2010 · CA · contact PI

Population-based study of DNA damage response markers of prognosis in breast canc$199,825

P50 · FY2010 · CA · contact PI

Measurement of Cancer-Associated Biomarker Proteins in Complex Biological Samples$3,205,352

RC2 · FY2009 · CA · contact PI

Protein biomarker dosimetry$625,198

U19 · FY2009 · AI · contact PI

Cross-species network approach to predict epistatic cancer susceptibility genes$579,999

R01 · FY2009 · CA · contact PI

Minimizing mass panic with saliva tests for radiation exposure$440,000

R01 · FY2009 · AI · contact PI

Phenotype-based approach to find gene interactions underlying breast cancer risk$267,520

R01 · FY2009 · CA · contact PI

Protein biomarker dosimetry$623,407

U19 · FY2008 · AI · contact PI

Cross-species network approach to predict epistatic cancer susceptibility genes$565,632

R01 · FY2008 · CA · contact PI

Minimizing mass panic with saliva tests for radiation exposure$437,340

R01 · FY2008 · AI · contact PI

Phenotype-based approach to find gene interactions underlying breast cancer risk$267,520

R01 · FY2008 · CA · contact PI

Protein biomarker dosimetry$569,839

U19 · FY2007 · AI · contact PI

Phenotype-based approach to find gene interactions underlying breast cancer risk$267,520

R01 · FY2007 · CA · contact PI

Protein biomarker dosimetry$512,812

U19 · FY2006 · AI · contact PI

Protein biomarker dosimetry$499,851

U19 · FY2005 · AI